Journal Of Clinical Oncology Publishes Clinical Trial Results Of VELCADE Combination In Aggressive Subtypes Of Non-Hodgkin LymphomaPosted: March 10, 2011
Phase II results of a Weill Cornell-sponsored clinical trial examining VELCADE® (bortezomib) in patients with previously untreated aggressive lymphoma were published in February 2011 in the Journal of Clinical Oncology. The study was designed to examine the efficacy of VELCADE in combination with the current standard of care (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP) in 76 patients with two aggressive subtypes of lymphoma: mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL).
Dr. John Leonard, the Clinical Director of the Weill Cornell Center for Lymphoma and Myeloma, is the the principal investigator of the study. Click here to read the news release summarizing the results of the study. Click here to read the published research paper in the Journal of Clinical Oncology.